Study, Year | Study design | Follow-up | Treatment | Administered daily dose | control | Clinical outcome | Patients | No. of patients | |||
---|---|---|---|---|---|---|---|---|---|---|---|
TC | TG | LDL | HDL | ||||||||
Asadi et al. (2019) | Randomized, double-blinded, placebo-controlled study | 12 weeks | Hydroalcoholic extract of M. officinalis | 700 mg/d- two capsules per day (350 mg) | Placebo | ↓ | ↓* | ↑ | ↑** | Type 2 diabetes | 62 |
Jandaghi et al. (2016) | Randomized, double-blinded, placebo-controlled study | 2 months | M. officinalis leaf powder | 3000 mg/d- three capsules per day (1000 mg) | Placebo | ↓ | ↓ | ↓* | ↓ | Borderline hyperlipidemia | 58 |
Javid et al. (2018) | Randomized, double-blinded, placebo-controlled study | 8 weeks | M. officinalis leaf powder | 3 g per day (3 capsules) | Placebo | ↓*** | ↓*** | ↓*** | ↑*** | Chronic stable angina | 73 |
Kheirkhah et al. (2021) | Randomized open-label controlled trial | 12 weeks | Tea Bag of M. officinalis | 2 gr twice per day (4 gr) | Placebo | ↓** | ↓* | ↓ | ↑ | Premature ventricular contraction | 59 |
Kim et al. 1800 (2023) | Randomized, double-blinded, placebo-controlled study | 24 weeks | M. officinalis extract | 1800 mg/d ALS-L1023 | Placebo | ↑ | ↓ | ↓ | ↑ | Non-Alcoholic Fatty Liver Disease | 33 |
Kim et al. 1200 (2023) | Randomized, double-blinded, placebo-controlled study | 24 weeks | M. officinalis extract | 1200 mg/d ALS-L1023 | Placebo | ↓* | ↓* | ↓* | ↑ | Non-Alcoholic Fatty Liver Disease | 32 |